Ascletis raises $100 million for development

Wednesday, April 6, 2011

Ascletis, a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics will form and complete a Series A private equity financing. Ascletis has raised $100 million in committed financing.  The investors, led by Hangzhou Binjiang Investment Holding, included private entrepreneurs from China and other countries including the U.S., according to Fierce Biotech.

[Read More]